Kingsley Biotech announced that it had previously announced CARVYKTI's preliminary sales for the quarter ended March 31, 2026 and June 30, 2026. Legend announced on October 13, 2026 that CARVYKTI's net trade sales for the quarter ended September 30, 2026 were approximately US$710 million. This data was based on information provided by Janssen, and neither Legend nor Kingsley independently verified its accuracy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.